Plain-English translation of NCT06793956 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of two medications—sintilimab and linperlisib—to treat a rare type of blood cancer called extranodal NK/T-cell lymphoma. This treatment is designed for people whose cancer has come back or stopped responding to earlier chemotherapy. The study will help doctors learn whether giving these two medications together is safe and effective.
Many people with this rare lymphoma do not respond well to standard chemotherapy, and their cancer often comes back. This trial exists to find out whether combining these two medications in a new way might give patients who have run out of other options a better chance at fighting their cancer.
You likely qualify if…
You likely don't qualify if…
You would take both medications by mouth as part of an open-label study, meaning you and your doctors will know exactly what you're receiving. You will have regular visits to the study center for check-ups, blood tests, and imaging scans to see how your body is responding. The study is designed to include about 12 patients and will help determine the right dose and whether this combination is safe and helpful.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Sun Yat-sen University
Enrollment target
~12 participants
Started
February 2025
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qingqing Cai, MD. PhD.
Sun Yat-sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.